Clark G M, McGuire W L
Breast Cancer Res Treat. 1983;3 Suppl:S69-72. doi: 10.1007/BF01855130.
Estrogen receptor (ER) has been well documented as an important predictor of long disease-free intervals and survival for patients with primary breast cancer (1). In advanced breast cancer it has been hypothesized that the presence of progesterone receptor (PR) might be a more sensitive marker for predicting response to endocrine therapy (2, 3). We have recently found that PR was more important than ER in predicting disease-free survival for a group of patients with stage-II breast disease that was treated according to a randomized protocol (Clark et al., submitted for publication). This report examines the generality of that result by extending our analysis to include patients from other institutions. The additional patients were not treated according to a rigid clinical protocol, but rather received treatments in much the same way as the majority of breast cancer patients in a community practice. Of interest was whether the relationship between steroid receptors and disease-free survival that we have previously reported would hold with this new group of patients with different demographic and treatment profiles. The relationships between steroid receptor levels and both disease-free and overall survival were examined in detail.
雌激素受体（ER）已被充分证明是原发性乳腺癌患者无病生存期和生存的重要预测指标（1）。在晚期乳腺癌中，有人推测孕激素受体（PR）的存在可能是预测内分泌治疗反应的更敏感标志物（2,3）。我们最近发现，在一组按照随机方案治疗的II期乳腺癌患者中，PR在预测无病生存期方面比ER更重要（Clark等人，待发表）。本报告通过扩展分析以纳入来自其他机构的患者来检验该结果的普遍性。这些额外的患者并非按照严格的临床方案进行治疗，而是与社区实践中大多数乳腺癌患者的治疗方式大致相同。令人感兴趣的是，我们之前报道的类固醇受体与无病生存期之间的关系在这组具有不同人口统计学和治疗特征的新患者中是否依然成立。我们详细研究了类固醇受体水平与无病生存期和总生存期之间的关系。
